Authors
Ranson, Malcolm RAffiliation
University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK. malcolm.ranson@man.ac.ukIssue Date
2003-10
Metadata
Show full item recordAbstract
Abgenix and Amgen (formerly Immunex) are developing ABX-EGF, a human monoclonal antibody against the epidermal growth factor receptor, for potential use in the treatment of cancer. ABX-EGF is undergoing phase II trials in patients with renal, colorectal, prostate and non-small-cell lung cancers. By July 2002, phase III trials for these indications were planned to start in 2003.Citation
Technology evaluation: ABX-EGF, Abgenix/Amgen. 2003, 5 (5):541-6 Curr. Opin. Mol. Ther.Journal
Current Opinion in Molecular TherapeuticsPubMed ID
14601524Type
ArticleLanguage
enISSN
1464-8431Collections
Related articles
- Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
- Authors: Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM
- Issue date: 2004 Mar 1
- Technology evaluation: bevacizumab, Genentech/Roche.
- Authors: Salgaller ML
- Issue date: 2003 Dec
- Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.
- Authors: Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG
- Issue date: 2001 Apr
- Panitumumab the first fully human monoclonal antibody: from the bench to the clinic.
- Authors: Cohenuram M, Saif MW
- Issue date: 2007 Jan
- Technology evaluation: Onyvax-105, Onyvax.
- Authors: Blumenthal RD
- Issue date: 2003 Dec